Obesity Pillars最新文献

{"title":"Neuropathy of Diabetes Following Initiation of a Low-Carbohydrate Diet: Case Report","authors":"Mark Jamal Sahyouni,&nbsp;Luis Anthony Acevedo,&nbsp;Sofia Cristina Rodriguez,&nbsp;Justin Armond Chiles,&nbsp;Nicholas Joseph Pennings","doi":"10.1016/j.obpill.2024.100115","DOIUrl":"10.1016/j.obpill.2024.100115","url":null,"abstract":"<div><h3>Introduction</h3><p>This case study portrays an unusual case of treatment-induced neuropathy of diabetes (TIND) in a patient with uncontrolled type 2 diabetes (T2D) who achieved rapid improvement in glucose control primarily with dietary intervention. Initial presentation was 50-year-old white male with a long-standing history of obesity and a family history of T2D with a screening glucose level &gt;500mg/dL by glucometer, HbA1c of 14.9%, and initial weight 213lbs.</p></div><div><h3>Methods</h3><p>The initial intervention included a low-carbohydrate diet, metformin, and a continuous glucose monitor (CGM). Semaglutide was added after seven days.</p></div><div><h3>Results</h3><p>His glycemia was within the target range within three weeks. Four weeks after initiation of therapy, he developed TIND symptoms consisting of burning, tightness, and numbness of bilateral feet along with 10/10 pain. At three months, his HbA1c dropped to 6.9% and his weight to 195lbs. Treatment of his TIND reduced his pain from 10/10 to 2/10.</p></div><div><h3>Conclusion</h3><p>Whereas TIND is commonly associated with the use of insulin or sulfonylureas, this study adds evidence to the paucity of literature regarding TIND precipitated by dietary intervention.</p></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"11 ","pages":"Article 100115"},"PeriodicalIF":0.0,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667368124000172/pdfft?md5=5264353f4fd41999bd887942c0829d18&pid=1-s2.0-S2667368124000172-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141402815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In-hospital outcomes in metabolically healthy and unhealthy individuals over 65 years of age with obesity undergoing percutaneous intervention for acute coronary syndrome: A nationwide propensity-matched analysis (2016–2020)","authors":"Rupak Desai ,&nbsp;Aobo Li ,&nbsp;Avilash Mondal ,&nbsp;Sashwat Srikanth ,&nbsp;Alka Farmer ,&nbsp;Lin Zheng","doi":"10.1016/j.obpill.2024.100114","DOIUrl":"https://doi.org/10.1016/j.obpill.2024.100114","url":null,"abstract":"<div><h3>Background</h3><p>The obesity paradox in patients with coronary artery disease is well established, but the role of the metabolic syndrome associated with obesity is not well studied. Our study aims to evaluate the in-hospital outcomes of percutaneous coronary intervention (PCI) in metabolically healthy individuals with obesity (MHO) and metabolically unhealthy (MUHO) individuals with obesity over 65 years of age with acute coronary syndrome (ACS) between 2016 and 2020.</p></div><div><h3>Methods</h3><p>This was a retrospective and observational study. Patients were identified through utilizing the National Inpatient Sample (NIS) Database (2016–2020) and ICD-10 codes. By employing a <em>t</em>-test and Pearson's Chi-square test, we assessed and contrasted the initial attributes, concurrent conditions, and results pertaining to all-cause mortality (ACM), cardiogenic shock (CS), length of stay (LOS), and hospitalization expense. Moreover, propensity score matching was conducted in a 1:1 ratio with respect to age, gender, and race. We also utilized multivariable logistic regression to compare MHO and MUHO in terms of the impact on all-cause mortality.</p></div><div><h3>Results</h3><p>Out of a total of 135,395 patients identified, 2995 patients with MUHO were matched with 2995 MHO patients. Patients in the MUHO group had a higher prevalence of chronic pulmonary disease (24.9 % vs. 19.5 %), peripheral vascular disease (9.3 % vs. 6.7 %), hypothyroidism (16 % vs. 11.5 %), prior myocardial infarction (15.9 % vs. 6.2 %), and prior stroke (7.5 % vs. 2.8 %). Patients in the MHO group had a higher ACM (12.4 % vs. 2.8 %, p &lt; 0.001), CS (18.55 % vs. 7 %, p &lt; 0.001), stroke (2.2 % vs. 1 %, p &lt; 0.001), ventricular assist device insertions (5.2 % vs. 2.7 %, p &lt; 0.001), and IABP insertions (8.8 % vs. 3.8 %) compared to the MUHO cohort.</p></div><div><h3>Conclusion</h3><p>Our study revealed an obesity paradox in individuals over 65 years of age undergoing PCI demonstrating worse outcomes, including higher in-hospital mortality, CS, stroke, Ventricular assist device and IABP insertion in MHO patients compared to the MUHO cohort.</p></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"11 ","pages":"Article 100114"},"PeriodicalIF":0.0,"publicationDate":"2024-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667368124000160/pdfft?md5=0226893a08510e717f417b4649aaba52&pid=1-s2.0-S2667368124000160-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141164049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Special considerations for the child with obesity: An Obesity Medicine Association (OMA) clinical practice statement (CPS) 2024","authors":"Suzanne Cuda,&nbsp;Marisa Censani,&nbsp;Valerie O'Hara,&nbsp;Jennifer Paisley,&nbsp;Roohi Kharofa,&nbsp;Rushika Conroy,&nbsp;Brooke Sweeney,&nbsp;Cristina Fernandez,&nbsp;Meredith L. Dreyer Gillette,&nbsp;Nancy T. Browne","doi":"10.1016/j.obpill.2024.100113","DOIUrl":"10.1016/j.obpill.2024.100113","url":null,"abstract":"<div><h3>Background</h3><p>This Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) details assessment and management of the child with overweight or obesity. The term “child” is defined as the child between 2 and 12 years of age. Because children are in a continual state of development during this age range, we will specify when our discussion applies to subsets within this age range. For the purposes of this CPS, we will use the following definitions: overweight in the child is a body mass index (BMI) ≥ 85th and &lt;95th percentile, obesity in the child is a BMI ≥95th percentile, and severe obesity is a BMI ≥120% of the 95th percentile.</p></div><div><h3>Methods</h3><p>The information and clinical guidance in this <span>OMA</span> Clinical Practice Statement are based on scientific evidence, supported by medical literature, and derived from the clinical perspectives of the authors.</p></div><div><h3>Results</h3><p>This OMA Clinical Practice Statement provides an overview of prevalence of disease in this population, reviews precocious puberty in the child with obesity, discusses the current and evolving landscape of the use of anti-obesity medications in children in this age range, discusses the child with obesity and special health care needs, and reviews hypothalamic obesity in the child.</p></div><div><h3>Conclusions</h3><p>This OMA Clinical Practice Statement on the child with obesity is an evidence based review of the literature and an overview of current recommendations. This CPS is intended to provide a roadmap to the improvement of the health of children with obesity, especially those with metabolic, physiological, psychological complications and/or special healthcare needs. This CPS addresses treatment recommendations and is designed to help the clinician with clinical decision making.</p></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"11 ","pages":"Article 100113"},"PeriodicalIF":0.0,"publicationDate":"2024-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667368124000159/pdfft?md5=084fe606099e8a1bea3be311f1cde0e6&pid=1-s2.0-S2667368124000159-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141137374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of concomitant antiobesity medication use with endoscopic sleeve gastroplasty in clinical US settings","authors":"Khushboo Gala ,&nbsp;Wissam Ghusn ,&nbsp;Vitor Brunaldi ,&nbsp;Christopher McGowan ,&nbsp;Reem Z. Sharaiha ,&nbsp;Daniel Maselli ,&nbsp;Brandon Vanderwel ,&nbsp;Prashant Kedia ,&nbsp;Michael Ujiki ,&nbsp;Eric Wilson ,&nbsp;Eric J. Vargas ,&nbsp;Andrew C. Storm ,&nbsp;Barham K. Abu Dayyeh","doi":"10.1016/j.obpill.2024.100112","DOIUrl":"10.1016/j.obpill.2024.100112","url":null,"abstract":"<div><h3>Background</h3><p>To evaluate the weight loss outcomes of the large US cohort of patients undergoing endoscopic sleeve gastroplasty (ESG) with or without concomitant anti-obesity (AOM) use.</p></div><div><h3>Methods</h3><p>We performed a retrospective analysis of adult patients who underwent ESG from seven different sites, from January 1, 2020 to November 30, 2022. Percent total body weight loss (%TBWL) and %excess weight loss (%EWL) were calculated based on baseline weight at the procedure. Medication use was considered if the subject received a prescribed AOM during the study period. SPSS (version 29.0) was used for statistical analyses.</p></div><div><h3>Results</h3><p>A total of 1506 patients were included (1359 (90.2 %) no AOM use and 147 (9.8 %) AOM use). Patients who were on an active AOM at the time of the procedure had a significantly lower TBWL% as compared to patients not on AOMs at 6 months. At the 24-month visit, patients who were prescribed AOMs after the 12-month visit had a significantly higher TBWL% and EWL% as compared to patients who were on active AOM at the time of the procedure. There was no significant difference between classes of medications at any time point, however, patients on a GLP-1RA had a trend towards improved weight loss at 18 and 24 months.</p></div><div><h3>Conclusion</h3><p>In this large, real-world cohort of patients from the United States, data signal that with the use of pharmacotherapy at the appropriate time, patients can achieve optimal results.</p></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"11 ","pages":"Article 100112"},"PeriodicalIF":0.0,"publicationDate":"2024-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667368124000147/pdfft?md5=ae8e9cd8ce4d7e051f284d376bfc6c29&pid=1-s2.0-S2667368124000147-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141043930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stronger control of eating 3 months after sleeve gastrectomy predicts successful weight loss outcomes at one year","authors":"Ellina Lytvyak ,&nbsp;Amir Zarrinpar ,&nbsp;Cecilia Dalle Ore ,&nbsp;Euyhyun Lee ,&nbsp;Keila Yazdani-Boset ,&nbsp;Santiago Horgan ,&nbsp;Eduardo Grunvald","doi":"10.1016/j.obpill.2024.100111","DOIUrl":"https://doi.org/10.1016/j.obpill.2024.100111","url":null,"abstract":"<div><h3>Background</h3><p>Weight loss response to sleeve gastrectomy (SG) is variable and predicting the effectiveness of surgery is challenging and elusive. The aim of our study was to assess and quantify the association between eating control and weight loss outcomes and identify the control of eating (CoE) attributes during the early postoperative period that might predict good vs. poor response to SG at one year.</p></div><div><h3>Methods</h3><p>A prospective longitudinal cohort study using the Control of Eating Questionnaire (CoEQ) was designed as a series before and at 3-, 6-, and 12-months post-SG. Primary outcomes were changes in CoE attributes and percent of total weight loss (%TWL) 12-months post-surgery. Subjects were categorized based on %TWL as good (GR, ≥25 %) or poor responders (PR, &lt;25 %). A receiver operating characteristic and logistic regression analyses were performed.</p></div><div><h3>Results</h3><p>We included 41 participants (80.5% females, 51.2% Hispanic, mean age 41.7±10.6, median baseline body mass index (BMI) 43.6 kg/m² [range 35.2–66.3]) who completed the CoEQ at all four timepoints. The “Difficulty to control eating” score at 3 months revealed the highest area under the curve (AUC) (AUC 0.711; 95%CI 0.524–0.898; p=0.032). In a trade-off between a high Youden index and high sensitivity, the “Difficulty to control eating” score of 7 at 3 months was identified as the optimal cut-off for distinguishing between GRs and PRs. Score ≤7 at 3 months was strongly independently associated with a successful weight loss target of 25%TWL at one-year post-SG (Relative Risk 4.43; 95%CI 1.06–18.54; p=0.042).</p></div><div><h3>Conclusion</h3><p>“Difficulty to control eating” score at 3 months post-SG is an independent early predictor of optimal response (achieving a successful TWL target of ≥25 % at one-year post-SG). Our results support the utility of this easy-to-administer validated tool for predicting the effectiveness of SG and may assist in identifying individuals with suboptimal response early and helping them with interventions to attain optimal weight loss targets.</p></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"11 ","pages":"Article 100111"},"PeriodicalIF":0.0,"publicationDate":"2024-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667368124000135/pdfft?md5=683e2eabbbb146969ab1f77cd4840471&pid=1-s2.0-S2667368124000135-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140900997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differentiating monogenic and syndromic obesities from polygenic obesity: Assessment, diagnosis, and management","authors":"Angela K. Fitch ,&nbsp;Sonali Malhotra ,&nbsp;Rushika Conroy","doi":"10.1016/j.obpill.2024.100110","DOIUrl":"10.1016/j.obpill.2024.100110","url":null,"abstract":"<div><h3>Background</h3><p>Obesity is a multifactorial neurohormonal disease that results from dysfunction within energy regulation pathways and is associated with increased morbidity, mortality, and reduced quality of life. The most common form is polygenic obesity, which results from interactions between multiple gene variants and environmental factors. Highly penetrant monogenic and syndromic obesities result from rare genetic variants with minimal environmental influence and can be differentiated from polygenic obesity depending on key symptoms, including hyperphagia; early-onset, severe obesity; and suboptimal responses to nontargeted therapies. Timely diagnosis of monogenic or syndromic obesity is critical to inform management strategies and reduce disease burden. We outline the physiology of weight regulation, role of genetics in obesity, and differentiating characteristics between polygenic and rare genetic obesity to facilitate diagnosis and transition toward targeted therapies.</p></div><div><h3>Methods</h3><p>In this narrative review, we focused on case reports, case studies, and natural history studies of patients with monogenic and syndromic obesities and clinical trials examining the efficacy, safety, and quality of life impact of nontargeted and targeted therapies in these populations. We also provide comprehensive algorithms for diagnosis of patients with suspected rare genetic causes of obesity.</p></div><div><h3>Results</h3><p>Patients with monogenic and syndromic obesities commonly present with hyperphagia (ie, pathologic, insatiable hunger) and early-onset, severe obesity, and the presence of hallmark characteristics can inform genetic testing and diagnostic approach. Following diagnosis, specialized care teams can address complex symptoms, and hyperphagia is managed behaviorally. Various pharmacotherapies show promise in these patient populations, including setmelanotide and glucagon-like peptide-1 receptor agonists.</p></div><div><h3>Conclusion</h3><p>Understanding the pathophysiology and differentiating characteristics of monogenic and syndromic obesities can facilitate diagnosis and management and has led to development of targeted pharmacotherapies with demonstrated efficacy for reducing body weight and hunger in the affected populations.</p></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"11 ","pages":"Article 100110"},"PeriodicalIF":0.0,"publicationDate":"2024-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667368124000123/pdfft?md5=ef18eb01d9e247c0054d2b3730d24d2e&pid=1-s2.0-S2667368124000123-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140766442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Obesity pillars roundtable: Body mass index and body composition in black and female individuals. Race-relevant or racist? Sex-relevant or sexist?” [Obesity Pillars 4C (2022) 100044]","authors":"Harold Edward Bays ,&nbsp;Sylvia Gonsahn-Bollie ,&nbsp;Courtney Younglove ,&nbsp;Sean Wharton","doi":"10.1016/j.obpill.2024.100105","DOIUrl":"10.1016/j.obpill.2024.100105","url":null,"abstract":"","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"10 ","pages":"Article 100105"},"PeriodicalIF":0.0,"publicationDate":"2024-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S266736812400007X/pdfft?md5=e2ec63f3922a3ed3a882c1af3a0d02b5&pid=1-s2.0-S266736812400007X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140281860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association 2024","authors":"Harold Edward Bays,&nbsp;Carol Kirkpatrick,&nbsp;Kevin C. Maki,&nbsp;Peter P. Toth,&nbsp;Ryan T. Morgan,&nbsp;Justin Tondt,&nbsp;Sandra Michelle Christensen,&nbsp;Dave Dixon,&nbsp;Terry A. Jacobson","doi":"10.1016/j.obpill.2024.100108","DOIUrl":"10.1016/j.obpill.2024.100108","url":null,"abstract":"<div><h3>Background</h3><p>This joint expert review by the Obesity Medicine Association (OMA) and National Lipid Association (NLA) provides clinicians an overview of the pathophysiologic and clinical considerations regarding obesity, dyslipidemia, and cardiovascular disease (CVD) risk.</p></div><div><h3>Methods</h3><p>This joint expert review is based upon scientific evidence, clinical perspectives of the authors, and peer review by the OMA and NLA leadership.</p></div><div><h3>Results</h3><p>Among individuals with obesity, adipose tissue may store over 50% of the total body free cholesterol. Triglycerides may represent up to 99% of lipid species in adipose tissue. The potential for adipose tissue expansion accounts for the greatest weight variance among most individuals, with percent body fat ranging from less than 5% to over 60%. While population studies suggest a modest increase in blood low-density lipoprotein cholesterol (LDL-C) levels with excess adiposity, the adiposopathic dyslipidemia pattern most often described with an increase in adiposity includes elevated triglycerides, reduced high density lipoprotein cholesterol (HDL-C), increased non-HDL-C, elevated apolipoprotein B, increased LDL particle concentration, and increased small, dense LDL particles.</p></div><div><h3>Conclusions</h3><p>Obesity increases CVD risk, at least partially due to promotion of an adiposopathic, atherogenic lipid profile. Obesity also worsens other cardiometabolic risk factors. Among patients with obesity, interventions that reduce body weight and improve CVD outcomes are generally associated with improved lipid levels. Given the modest improvement in blood LDL-C with weight reduction in patients with overweight or obesity, early interventions to treat both excess adiposity and elevated atherogenic cholesterol (LDL-C and/or non-HDL-C) levels represent priorities in reducing the risk of CVD.</p></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"10 ","pages":"Article 100108"},"PeriodicalIF":0.0,"publicationDate":"2024-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S266736812400010X/pdfft?md5=30611622cac9e760720255876287e7b2&pid=1-s2.0-S266736812400010X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140282296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Presentation of a weight bias internalization tool for use in pregnancy and a call for future research: A commentary","authors":"Taniya S. Nagpal ,&nbsp;Nicole Pearce ,&nbsp;Kristi B. Adamo","doi":"10.1016/j.obpill.2024.100107","DOIUrl":"https://doi.org/10.1016/j.obpill.2024.100107","url":null,"abstract":"<div><h3>Background</h3><p>Emerging evidence has shown that weight stigma is a concern during pregnancy, with several studies documenting common sources including healthcare, the media and interpersonal networks. Experiencing weight stigma may lead to weight bias internalization (WBI), whereby individuals accept and self-direct negative weight-related stereotypes, and limited research has assessed this in the context of pregnancy. Pregnancy is unique in terms of weight changes as many individuals will experience gestational weight gain (GWG). Accordingly, a WBI tool that accounts for GWG may be a more population-specific resource to use.</p></div><div><h3>Methods</h3><p>This commentary presents a pregnancy-specific WBI tool that accounts for GWG. The validated Adult WBI scale was modified to include ‘pregnancy weight gain’. This commentary also presents a brief summary of research that has assessed WBI in pregnancy and recommendations for future work.</p></div><div><h3>Results</h3><p>Recommended future work includes validation of the pregnancy-specific WBI tool and prospective examinations of weight stigma and WBI in pregnancy and implications on maternal and newborn outcomes.</p></div><div><h3>Conclusion</h3><p>Ultimately this research may inform development of interventions and resources to mitigate weight stigma and WBI in pregnancy and overall may contribute to improving prenatal outcomes and experiences.</p></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"10 ","pages":"Article 100107"},"PeriodicalIF":0.0,"publicationDate":"2024-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667368124000093/pdfft?md5=9573824bef1ff7702c798c57ee74ea4b&pid=1-s2.0-S2667368124000093-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140141402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Weight-centric prevention of cancer","authors":"Diego Anazco ,&nbsp;Andres Acosta ,&nbsp;Elizabeth J. Cathcart-Rake ,&nbsp;Stacy D. D'Andre ,&nbsp;Maria D. Hurtado","doi":"10.1016/j.obpill.2024.100106","DOIUrl":"https://doi.org/10.1016/j.obpill.2024.100106","url":null,"abstract":"<div><h3>Background</h3><p>The link between excess adiposity and carcinogenesis has been well established for multiple malignancies, and cancer is one of the main contributors to obesity-related mortality. The potential role of different weight-loss interventions on cancer risk modification has been assessed, however, its clinical implications remain to be determined. In this clinical review, we present the data assessing the effect of weight loss interventions on cancer risk.</p></div><div><h3>Methods</h3><p>In this clinical review, we conducted a comprehensive search of relevant literature using MEDLINE, Embase, Web of Science, and Google Scholar databases for relevant studies from inception to January 20, 2024. In this clinical review, we present systematic reviews and meta-analysis, randomized clinical trials, and prospective and retrospective observational studies that address the effect of different treatment modalities for obesity in cancer risk. In addition, we incorporate the opinions from experts in the field of obesity medicine and oncology regarding the potential of weight loss as a preventative intervention for cancer.</p></div><div><h3>Results</h3><p>Intentional weight loss achieved through different modalities has been associated with a reduced cancer incidence. To date, the effect of weight loss on the postmenopausal women population has been more widely studied, with multiple reports indicating a protective effect of weight loss on hormone-dependent malignancies. The effect of bariatric interventions as a protective intervention for cancer has been studied extensively, showing a significant reduction in cancer incidence and mortality, however, data for the effect of bariatric surgery on certain specific types of cancer is conflicting or limited.</p></div><div><h3>Conclusion</h3><p>Medical nutrition therapy, exercise, antiobesity medication, and bariatric interventions, might lead to a reduction in cancer risk through weight loss-dependent and independent factors. Further evidence is needed to better determine which population might benefit the most, and the amount of weight loss required to provide a clinically significant preventative effect.</p></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"10 ","pages":"Article 100106"},"PeriodicalIF":0.0,"publicationDate":"2024-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667368124000081/pdfft?md5=e755674535ec16622e68e439c1ba90c2&pid=1-s2.0-S2667368124000081-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140063300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}